Multi-year agreement focused on validation of the platform as well as advancing translational research capabilities
MADISON, Wis., Feb. 20, 2024 /PRNewswire/ — Elephas Biosciences Corporation (Elephas), a biotechnology company, today announced that it will collaborate on the development of an oncology imaging diagnostics platform to predict response to immunotherapy with Mayo Clinic Comprehensive Cancer Center. The Elephas platform utilizes live patient biopsies with intact native tumor architecture and treats them with potential immunotherapies to predict response to treatment. The basis of the platform is to visualize immune cell activity including T cell activation and cytotoxic mediated killing.